ACDN-01

Small molecule

AAscidian Therapeutics, Inc

ACDN-01 is one of 34 small molecule programs targeting Retinopathy. It is currently in development.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

RetinopathyActive, not recruiting

RetinopathyPhase 1/Phase 2

Active, not recruiting

Competition

Competitive Landscape

43 competitors in Retinopathy

#DrugCompanyPhaseTrials

Inspra

PPfizer's Upjohn has merged with Mylan to form Viatris Inc.

Approved

5 2

Tricor

JJagotec

Approved

1 3

Lucentis

Roche

Phase 3

5 4

Betadine

BBecton, Dickinson and Company

Vabysmo

1 6

Synalar

EEurofarma Laboratorios S.A.

Phase 3

2 7

Avastin

BBio-Thera Solutions

Phase 3

1 8

Kenalog

BBausch Health Americas, Inc.

Phase 3

1 9

Circadin

NNeurim Pharmaceuticals Ltd.

Phase 3

1 10

Inspra /eplerenone

Bayer

Approved

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2030

Phase 1/2Recruiting

Retinopathy

NCT06467344

Clinical

Trials by Indication[1]

Retinopathy1 trial

Study to Evaluate ACDN-01 in ABCA4-related Stargardt Retinopathy (STELLAR)

Recruiting·AAscidian Therapeutics, Inc·Phase 1/2·NCT06467344·15 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for ACDN-01. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — ACDN-01 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for ACDN-01. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Ascidian Therapeutics, Inc company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Company: AAscidian Therapeutics, Inc

ACDN-01

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2030

Trials by Indication[1]

Retinopathy1 trial

References

Drug Info

Quick Facts

Related News